The Autoinjectors Market is expected to witness a growth rate of 14-16% by 2028. The key factors driving the market are the ...

People on the drug had less liver inflammation and scarring They also lost weight and had better liver function THURSDAY, May 1, 2025 (HealthDay News) -- The cutting-edge weight-loss drug Ozempic ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

People on the drug had less liver inflammation and scarring They also lost weight and had better liver function THURSDAY, May 1, 2025 (HealthDay News) -- The cutting-edge weight-loss drug ...

People on the drug had less liver inflammation and scarring They also lost weight and had better liver function Originally published on healthday.com, part of the BLOX Digital Content Exchange.

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. Oligonucleotides work as ...